Ionis, Roche's sefaxersen cuts proteinuria 43.1% versus placebo in Phase 3 IgAN trial

By Public Technologies
  • Ionis Pharmaceuticals partner Roche reported Phase 3 results showing sefaxersen significantly reduced proteinuria versus placebo in adults with IgA nephropathy.
  • Results were presented at the American Society of Nephrology Kidney Week 2026; no new safety signals emerged.
  • The ongoing trial will assess longer-term kidney function; Roche plans to share data with health authorities.
  • Licensed to Roche, sefaxersen could generate regulatory and sales milestone payments for Ionis, alongside tiered royalties on net sales.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610231337BIZWIRE_USPR_____20261022_BW913461) on October 23, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.